Abstract #0914
Assessment of the response of colorectal tumours to imatinib mesylate therapy using carbogen and hypercapnia gas challenges
Miguel R. Goncalves 1 , Simon Walker-Samuel 1 , Rajiv Ramasawmy 1,2 , Sean P. Johnson 2 , R. Barbara Pedley 2 , and Mark F. Lythgoe 1
1
UCL Centre for Advanced Biomedical Imaging,
Division of Medicine, London, United Kingdom,
2
UCL
Cancer Institute, London, United Kingdom
We present the results of a tumour therapy study with
the antiangiogenic agent imatinib mesylate, which was
assessed using gradient-echo MRI alongside hyperoxia and
hypercapnia challenges. Median carbogen-ΔR2*,
carbogen-ΔR1 and hypercapnia-ΔGRE-SI did not change with
therapy. However, significant changes in the spatial
heterogeneity of carbogen-ΔR2* and hypercapnia-ΔSI were
observed. These results are possibly due to the combined
effect of a number of localised phenomena, given the
heterogeneous nature of the tumour vasculature.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
